Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26281
Abstract: Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subgroup of precursor B-cell (BCP) ALL. In the phase 3 TOWER trial (NCT02013167), blinatumomab demonstrated superior overall survival (OS) than standard of care chemotherapy (SOC)… read more here.
Keywords: efficacy safety; safety blinatumomab; blinatumomab; patients like ... See more keywords